Portal de Periódicos da CAPES

Evidence-based guideline update: Treatment of essential tremor

2011; Lippincott Williams & Wilkins; Volume: 77; Issue: 19 Linguagem: Inglês

10.1212/wnl.0b013e318236f0fd

1526-632X

Theresa A. Zesiewicz, Rodger J. Elble, Elan D. Louis, Gary Gronseth, William G. Ondo, Richard B. Dewey, Michael S. Okun, K.L. Sullivan, William J. Weiner,

Glycogen Storage Diseases and Myoclonus

This evidence-based guideline is an update of the 2005 American Academy of Neurology practice parameter on the treatment of essential tremor (ET).A literature review using MEDLINE, EMBASE, Science Citation Index, and CINAHL was performed to identify clinical trials in patients with ET published between 2004 and April 2010.Conclusions and recommendations for the use of propranolol, primidone (Level A, established as effective); alprazolam, atenolol, gabapentin (monotherapy), sotalol, topiramate (Level B, probably effective); nadolol, nimodipine, clonazepam, botulinum toxin A, deep brain stimulation, thalamotomy (Level C, possibly effective); and gamma knife thalamotomy (Level U, insufficient evidence) are unchanged from the previous guideline. Changes to conclusions and recommendations from the previous guideline include the following: 1) levetiracetam and 3,4-diaminopyridine probably do not reduce limb tremor in ET and should not be considered (Level B); 2) flunarizine possibly has no effect in treating limb tremor in ET and may not be considered (Level C); and 3) there is insufficient evidence to support or refute the use of pregabalin, zonisamide, or clozapine as treatment for ET (Level U).